Ponatinib (Iclusig; Takeda) combined with reduced-intensity chemotherapy achieved higher minimal residual disease-negative complete remission rates in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia compared to imatinib.
Investigational migraine drug produces significant effects on both freedom-from-pain and MBS-free endpoints at 3 hours post administration and at additional efficacy measurement timepoints of 4, 6, 12, 24 and 48 hours.
cobas MPXV targets 2 different regions of the monkeypox virus genome that are less prone to mutations than other parts of the genome.
Belantamab mafodotin-blmf is a first-in-class, anti-B-cell maturation antigen therapy indicated for adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies.
Tremelimumab-actl (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy approved for the treatment of adults with metastatic non–small cell lung cancer without sensitizing EGFR mutation or ALK aberrations.
FDA approves brentuximab vedotin for the treatment of patients aged 2 years and older with previously untreated, high-risk classical Hodgkin lymphoma, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.
Tenofovir alafenamide is a nucleoside analog reverse transcriptase inhibitor specifically indicated to treat HBV in adults with compensated liver disease.
New presentation offers health care providers with a more convenient, ready-to-use immunization option for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W.
Zanubrutinib (Brukinsa) is a small molecule Bruton’s tyrosine kinase inhibitor under evaluation as a monotherapy and in combination with other treatments for various B-cell malignancies.
Nerivio (Theranica) remote electrical neuromodulation device found to offer similar pain relief as standard care medications as an alternative for patients with chronic migraine.
Furosemide injection 80 mg/10 mL (Furoscix; scPharmaceuticals) is indicated for the at-home treatment of congestion caused by fluid overload in adult patients with New York Heart Association Class II/III chronic heart failure.
Prior evidence regarding the safety and efficacy of the combination of apremilast and phototherapy was lacking, prompting researchers to investigate further.
Bulevirtide is a synthetic myristoylated peptide derived from the pre-S1 domain of the hepatitis B virus large surface protein.
Futibatinib (Lytgobi, Taiho Oncology, Inc) is indicated for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements.
Belantamab mafodotin plus lenalidomide and dexamethasone was found tolerable with no new safety signals and enhanced response rates in patients with multiple myeloma.
Ivosidenib plus azacitidine shows benefits in event-free survival, overall survival, and clinical responses compared with placebo in patients with IDH1-mutated acute myeloid leukemia.
Dupilumab is the first and only medicine approved specifically for the treatment of prurigo nodularis in the United States.
Iheezo is a sterile, single use ophthalmic gel preparation.
Bevacizumab-adcd (Vegzelma) is indicated for the treatment of nonsquamous non–small cell lung cancer; recurrent glioblastoma; metastatic colorectal cancer; persistent, recurrent, or metastatic cervical cancer; metastatic renal cell carcinoma; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.
KIN-2787 is a potential treatment for BRAF class II or III alteration-positive and/or NRAS mutation-positive, metastatic or unresectable, stage IIB to IV malignant melanoma.
Omidenepag isopropyl ophthalmic solution (Omlonti) eye drops are indicated to reduce elevated intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.
Innovative system reveals a pair of potential therapies for autosomal recessive polycystic kidney disease, which currently has no FDA-approved treatments.
Selpercatinib produced clinically meaningful and durable responses across a variety of tumor types in patients with RET-driven cancers.
Revised program will analyze the once-daily oral combination of doravirine 100 mg and a lower dose of islatravir in adults with HIV-1 infection.
NVG-111 is a humanized, tandem single-chain variable fragment ROR1 x CD3 BiTE being evaluated in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.
Prescribers signed a letter expressing concerns about recommendations for restrictions on compounded hormones, which millions of women and other patient populations rely on.
Case report describes severe complications from spontaneous bladder rupture caused by herpes zoster-associated urinary retention.
Deucravacitinib (Sotyktu) may become the new standard of care oral therapy for moderate-to-severe plaque psoriasis, according to investigators.
Pemigatinib is the first targeted therapy to gain FDA approval for the treatment of adult patients with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.
Ibrutinib (Imbruvica) is the first therapy to gain FDA approval for younger patients who had no prior treatment options for chronic graft-versus-host disease.
